Has Dolly Quispe Leveau, MD received payments from drug or device companies?

Yes. Drug and device makers reported $73,716 in general payments to Dolly Quispe Leveau, MD across 320 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Dolly Quispe Leveau, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Dolly Quispe Leveau, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Dolly Quispe Leveau, MD

Hematology & Oncology · Fort Wayne, INNPI 1821209370

Payments from drug & device makers

$73,716in general payments, 2019–2025

Across 320 payments — averaging $230.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Daiichi Sankyo Inc.$54K
Astellas Pharma US Inc$12K
Johnson & Johnson$1K
Merck$453
Pfizer$434
Pharmacyclics LLC, An Abbvie Company$415
plus $6K from 53 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Daiichi Sankyo Inc.	18	$53,921
Astellas Pharma US Inc	7	$11,914
Johnson & Johnson(2 entities)	25	$1,031
Merck	28	$453
Pfizer	18	$434
Pharmacyclics LLC, An Abbvie Company	13	$415
Sanofi	15	$390
Amgen	16	$370
E.r. Squibb & Sons, L.L.C.	15	$367
Athenex Pharmaceutical Division, LLC	2	$350
AstraZeneca(2 entities)	9	$320
Novartis	16	$303
AbbVie	10	$248
Eisai Inc.	8	$227
Takeda Pharmaceuticals U.S.A., Inc.	5	$224
Sobi, Inc	5	$169
Genentech USA, Inc.	10	$168
Regeneron Healthcare Solutions, Inc.	9	$163
Gilead(2 entities)	7	$153
Karyopharm Therapeutics Inc.	2	$146
Seagen Inc.	3	$141
Bristol Myers Squibb	6	$127
Verastem, Inc.	1	$122
AMAG Pharmaceuticals, Inc.	1	$118
Array Biopharma Inc	8	$105
Adaptive Biotechnologies Corporation	5	$103
Exelixis Inc.	2	$103
Foundation Medicine, Inc.	1	$98
Jazz Pharmaceuticals Inc.	5	$85
Ipsen Biopharmaceuticals, Inc	3	$73
Genmab U.S., Inc.	3	$69
Lilly USA, LLC	4	$65
Tersera Therapeutics LLC	2	$65
EMD Serono, Inc.	3	$53
Recordati_rare_diseases_inc.	2	$48
Beigene USA, Inc.	3	$44
Beone Medicines USA, Inc.	2	$41
Boehringer Ingelheim	2	$38
Bayer	2	$38
Puma Biotechnology, Inc.	2	$36
Acrotech Biopharma Inc.	2	$33
Incyte Corporation	2	$32
Caris MPI, Inc.	1	$23
Pharming Healthcare, Inc.	1	$22
Sun Pharmaceutical Industries Inc.	1	$22
Fortovia Therapeutics, Inc.	2	$21
AVEO Pharmaceuticals, Inc.	1	$20
Fennec Pharmaceuticals, Inc.	1	$19
G1 Therapeutics, Inc.	1	$19
ADC Therapeutics America, Inc.	1	$19
Novocure Inc.	1	$18
Secura Bio, Inc.	1	$17
Immunogen, Inc.	1	$17
Legend Biotech USA Inc.	1	$17
Morphosys, US Inc.	1	$16
Taiho Oncology, Inc.	1	$16
Dova Pharmaceuticals	1	$16
Epizyme, Inc.	1	$15
Spectrum Pharmaceuticals Inc.	1	$13

How this compares

$73,716 in reported general payments places this provider in the 70th percentile of 224 hematology & oncology providers in Indiana.

See all hematology & oncology providers in Indiana →

Medicare billing

Part B allowed, 2024

$1,213,833

Medicare patients

414

Services billed

64,430

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Fort Wayne

Zhentao ZhangFort Wayne$6.4M
Ahad SadiqFort Wayne$4M
Jeffrey LetzerFort Wayne$763K
Naga Malleswari VutukuriFort Wayne$340K
Melanie ClarkFort Wayne$281K
Robert MangesFort Wayne$270K
Sreenivasa NattamFort Wayne$122K
Praveen KolliparaFort Wayne$88K
Gregory DurmIndianapolis$22.7M
Nabil AdraIndianapolis$13.2M

See the full list for Indiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →